Hybrigenics receives clearance and funding for inecalcitol in psoriasis
This article was originally published in Scrip
Executive Summary
Hybrigenics has received a zero interest loan of €650,000 from OSEO, the French financial institution supporting innovation, to cover 45% of the costs of a Phase II study with oral inecalcitol in patients with moderate-to-severe psoriasis. AFSSAPS, the French drug agency, recently granted authorisation for the trial to proceed.